Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy

Hongmei Liu; Ruilong Zhang; Yunwei Niu; Yan Li; Chenmeng Qiao; Jie Weng; Jun Li; Xiaoning Zhang; Zuobing Xiao; Xin Zhang

doi:10.1039/C4RA14875D

Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy†

Hongmei Liu,‡^bc Ruilong Zhang,‡^bd Yunwei Niu,^a Yan Li,^bc Chenmeng Qiao,^e Jie Weng,^e Jun Li,^f Xiaoning Zhang,*^f Zuobing Xiao*^a and Xin Zhang*^ab

Author affiliations

* Corresponding authors

^a School of Perfume and Aroma Technology, Shanghai Institute of Technology, Shanghai, China
E-mail: xzb@sit.edu.cn, xzhang@ipe.ac.cn

^b National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China

^c University of Chinese Academy of Sciences, Beijing, China

^d Institute of Materials Science and Engineering, Ocean University of China, Qingdao, Shandong Province, China

^e Key Laboratory of Advanced Technologies of Materials, School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan, China

^f Collaborative Innovation Center for Biotherapy, School of Medicine, Tsinghua University, Beijing 100084, China
E-mail: drugman@tsinghua.edu.cn

Abstract

Hypoxia has a major role in tumor development and resistance to therapy. Therefore, the effective targeting and killing of hypoxic tumor cells is a key to successful tumor control. Here, we report the hypoxia-responsive prodrug micelles to deliver hydrophobic anticancer drug, which can selectively release the drugs to treat hypoxic tumor cells in a combined way. For this purpose, an azobenzene (AZO) bond, which imparts hypoxia sensitivity and specificity as cross linker, conjugated PEG–hexanethiol (PEG–C6) with combretastatin A-4 (CA4) to form PEG–C6–AZO–CA4 amphiphilic molecule. These PEG–C6–AZO–CA4 molecules self-assemble into micelles, which can encapsulate hydrophobic anticancer drug. The drug release behavior from PEG–C6–AZO–CA4 micelles was studied under normoxic or hypoxic conditions and the combinations of CA4 with hydrophobic drugs for tumor treatment in vitro were also investigated. As the first example of using AZO linkages to develop anticancer prodrug micelles as hydrophobic anticancer drugs delivery to kill the hypoxic tumor cells in a combination way, this study establishes PEG–C6–AZO–CA4 micelles as a promising drug delivery platform for hypoxic tumor therapy.

RSC Advances

Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy†

Abstract

Supplementary files

Article information

Download Citation

Permissions

Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy

Social activity

Search articles by author

Spotlight

Advertisements